|
|
|
|
bexarotene
An anticancer drug used to decrease the growth of some types of cancer cells. It belongs to the family of drugs called retinoids. Also called LGD1069. (National Cancer Institute)
Ligand settles patent royalty dispute with SRI Mar 14, 2005
...are owned by Menlo Park-based SRI and by La Jolla-based Burnham, said the settlement strengthens its intellectual property position for bexarotene, the active ... San Francisco Business Times,
Ligand and SRI/Burnham Agree to Settle Patent Interference on ... Mar 14, 2005
The company believes the settlement strengthens Ligand's intellectual property position for bexarotene, the active ingredient in the Targretin(R) products. ... PharmaLive.com (press release),
Rates climb on short-term bills Mar 15, 2005
Ligand had filed a patent interference action against the research groups, which had given Ligand exclusive licenses to their patents for the drug bexarotene. ... San Diego Union Tribune
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
Ligand's Targretin is Included on CMS List of Newly Covered ... Jun 28, 2004
Section 641 Demonstration Program under the Medicare Modernization Act of 2003 includes reimbursement under Medicare for Targretin(R) (bexarotene) for patients ... Business Wire (press release), CA -
Ligand and Investigators Present Exciting Scientific and Clinical ... Jun 7, 2004
Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) announced today that several clinical trials and in vitro studies on Targretin(R) (bexarotene), ONTAK(R ... Business Wire (press release), CA -
Resources from the National Cancer Institute on bexarotene:
|
|
|
